Related Experiment Video
Updated: Apr 19, 2026
10:44
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
14.0K
Population pharmacokinetics of pomalidomide
Yan Li1, Yejun Xu, Liangang Liu
1Translational Development and Clinical Pharmacology, Celgene Corporation, Summit, NJ, USA.
Journal of Clinical Pharmacology
|January 6, 2015
Summary
Pomalidomide shows consistent pharmacokinetics in multiple myeloma patients and healthy individuals. Drug exposure is higher in peripheral compartments for patients, with clearance unaffected by demographics or renal impairment.
Area of Science:
- Pharmacology
- Clinical Pharmacology
- Drug Metabolism
Background:
- Pomalidomide is an immunomodulatory agent used in multiple myeloma treatment.
- Understanding its pharmacokinetic profile is crucial for optimizing therapeutic outcomes.
- Population pharmacokinetic (PPK) modeling provides insights into drug behavior across diverse patient populations.
Purpose of the Study:
- To develop a population pharmacokinetic (PPK) model for pomalidomide.
- To evaluate the impact of demographic and disease-related factors on pomalidomide pharmacokinetics.
- To assess pomalidomide's drug exposure in healthy individuals versus multiple myeloma patients.
Main Methods:
- Developed a PPK model using data from six clinical trials.
- Included healthy participants (n=96) and multiple myeloma patients (n=144).
- Analyzed covariates including demographics and renal function (creatinine clearance, renal impairment).
Main Results:
- Systemic clearance of pomalidomide was similar in healthy subjects and multiple myeloma patients.
- Apparent peripheral volume of distribution and intercompartmental clearance were significantly higher in multiple myeloma patients.
- Pomalidomide clearance was not significantly affected by demographic factors (except gender, deemed clinically irrelevant) or renal impairment.
- Pomalidomide demonstrates preferential uptake by tumors in multiple myeloma patients.
Conclusions:
- Pomalidomide exhibits robust pharmacokinetic exposure.
- Drug exposure is higher in peripheral compartments of multiple myeloma patients.
- Pomalidomide's pharmacokinetics are not significantly influenced by demographic factors or renal impairment, suggesting predictable dosing.
Related Concept Videos
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
356
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
356
01:10Pharmacokinetics: Overview
12.0K
Pharmacokinetics is a scientific discipline that focuses on the journey of a drug within the body, encompassing four key stages: absorption, distribution, metabolism, and elimination. The first stage, absorption, involves the drug's transfer into the bloodstream. Several factors dictate the extent and speed of this process. For example, the liver often metabolizes oral drugs before they reach systemic circulation, leading to only partial absorption. In contrast, intravenous (IV)...
12.0K
01:14Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
113
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
113
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
919
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
919
01:23Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
118
Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s...
118
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
105
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
105